Valuation: Novacyt

Market Cap 30.92M 35.57M 28.78M 26.43M 49.9M 3.4B 50.67M 339M 133M 1.69B 134M 131M 5.67B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 32.88M 37.82M 30.6M 28.1M 53.06M 3.61B 53.88M 361M 142M 1.8B 142M 139M 6.03B EV / Sales 2026 *
1.08x
EV / Sales 2027 * 1.03x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 week-4.37%
1 month+4.92%
3 months+33.07%
6 months+4.02%
Current year+9.08%
1 week 0.42
Extreme 0.425
0.45
1 month 0.39
Extreme 0.39
0.48
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Date Insider Type Main position Quantity % Market Cap.
4/23/24 A Free

Chief Executive Officer

946,475 1.3401%
4/23/24 A Free

Chief Financial Officer

391,645 0.5545%
4/23/24 A Free

Chief Technology Officer

465,078 0.6585%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-4.37%-6.37%-41.17% 35.57M
-3.28%-1.67%-42.32%-47.92% 602M
+20.41%-27.10%+101.95% - 354M
+12.38%-3.65%-35.93%-0.29% 108M
-0.38%+2.32%+9.96%+62.58% 101M
Average +5.83%-6.24%+5.46%-6.70% 240.2M
Weighted average by Cap. +5.46%-8.31%+6.25%-28.37%

Financials

2026 *2027 *
Net sales 30.52M 35.11M 28.41M 26.09M 49.26M 3.35B 50.02M 335M 131M 1.67B 132M 129M 5.6B 34.86M 40.1M 32.45M 29.79M 56.26M 3.83B 57.13M 382M 150M 1.91B 151M 147M 6.39B
Net income - -
Net Debt 1.96M 2.25M 1.82M 1.67M 3.16M 215M 3.21M 21.46M 8.42M 107M 8.45M 8.26M 359M 4.84M 5.57M 4.51M 4.14M 7.81M 532M 7.94M 53.12M 20.85M 265M 20.92M 20.46M 888M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
31/07/26 €0.4265 -.--% 95,813
30/07/26 €0.4265 -2.63% 43,097
29/07/26 €0.4380 -2.34% 51,865
28/07/26 €0.4485 -0.33% 157,777
27/07/26 €0.4500 +0.90% 30,108

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock